---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-388621"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-09-11T11:45:19+00:00"
generated_at: "2026-09-11T11:50:47.935223+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.98
calibrated_materiality_score: 0.98
confidence: "high"
source: SEC EDGAR
---

# Karyopharm misses $15.8M debt payment, enters forbearance; going-concern doubt through Oct 15

## Summary
- Missed $15.8M principal installment due Sept 10, 2026 under Credit Agreement; events of default and cross-defaults triggered.
- Forbearance runs to Oct 15, 2026; no waiver of defaults, creditors reserve remedies; defaulted debt bears +2.00% interest.
- Issuing 20,000 shares of 0% convertible preferred stock at $1,000/share to pay $20M forbearance fees; conversion at $1.62/share.
- Liquidity funds operations only until Oct 15, 2026; absent new funding or deal, company unable to continue as going concern.
- Outstanding: ~$129M term loan, $15.6M 2028 notes, $108M 2029 notes; $113.5M future royalty obligations.

## SEC filing metadata
- accession: 0001193125-26-388621
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-09-11T11:45:19+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.98
- calibrated_materiality_score: 0.98
- confidence: high
- sec_items: 1.01, 2.04, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/0001193125-26-388621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/d94769d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-388621
- JSON: https://secwatch.observer/filing/0001193125-26-388621.json
- Plain text: https://secwatch.observer/filing/0001193125-26-388621.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.